Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities Blog Post
RADNOR, PA — April 1st, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has released a new version of the Simcyp™ Simulator for physiologically-based pharmacokinetic (PBPK) modeling.
How to Make 3rd Party Reconciliation in Clinical Data Management More Efficient Blog Post
Learn how to streamline 3rd party reconciliation in clinical data management with reusable standards, centralized communication & in-stream data validation.
MIDD’s Growing Role in Global Health: A Case Study of Primaquine Exposures in Lactating Women and Breastfed Infants Blog Post
May 22, 2025 – 11am-12pm ET
Building effective health economic models: key components for success Blog Post
Mohsen Yaghoubi Kinga Pacocha March 28, 2025 Editor’s note: This is the first in a series of four articles on the crucial role health economic modeling plays in evaluating the...
Mechanistic Modeling Guides Bispecific Antibody Design and Target Selection for Maximizing Therapeutic Window Blog Post
Download PDF Learn more about Assess™ QSP Software for Early Feasibility Assessment Assess™ is a revolutionary QSP modeling software that empowers researchers to make evidence-based decisions earlier in the drug...
How can the industry balance the need for faster drug approvals with the necessity of ensuring patient safety and efficacy? Blog Post
Certara’s Steve Sibley, Vice President Regulatory Strategy, is quoted in this Pharma's Almanac article about the challenges of balancing faster drug approvals with patient safety and efficacy. Read the article... BaseCase Community Meetup 2025 Blog Post
Virtual Event Date: June 5, 2025 Time: 8:30 AM – 12 PM ET 14:30 – 18:00 CET Join us for the BaseCase Community Meetup 2025, our first exclusive event designed...
The Revolution of Metadata Standardization with Clinical Metadata Repository (CMDR) Blog Post
April 22, 2025 – 10:00 am – 10:45 am, Japan time
